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Abstract
Background: Rapid identification and antimicrobial susceptibility testing (AST) of the causative agent(s) of
bloodstream infections can lead to prompt appropriate antimicrobial therapy. To shorten species identification,
in this study bacteria were recovered from monomicrobial blood cultures by serum separator tubes and spotted
onto the target plate for direct MALDI-TOF MS identification. Proper antibiotics were selected for direct AST
based on species identification. In order to obtain rapid AST results, bacteria were recovered from positive blood
cultures by two different protocols: by serum separator tubes (further referred to as PR1), or after a short-term
subculture in liquid medium (further referred to as PR2). The results were compared with those obtained by the
method currently used in our laboratory consisting in identification by MALDI-TOF and AST by Vitek 2 or
Sensititre on isolated colonies.
Results: The direct MALDI-TOF method concordantly identified with the current method 97.5 % of the Gram-negative
bacteria and 96.1 % of the Gram-positive cocci contained in monomicrobial blood cultures. The direct AST by PR1 and
PR2 for all isolate/antimicrobial agent combinations was concordant/correct with the current method for 87.8 and 90.
5 % of Gram-negative bacteria and for 93.1 and 93.8 % of Gram-positive cocci, respectively. In particular, 100 %
categorical agreement was found with levofloxacin for Enterobacteriaceae by both PR1 and PR2, and 99.0 and 100 %
categorical agreement was observed with linezolid for Gram-positive cocci by PR1 and PR2, respectively. There was no
significant difference in accuracy between PR1 and PR2 for Gram-negative bacteria and Gram-positive cocci.
Conclusions: This newly described method seems promising for providing accurate AST results. Most importantly,
these results would be available in a few hours from blood culture positivity, which would help clinicians to promptly
confirm or streamline an effective antibiotic therapy in patients with bloodstream infections.
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Background
Rapid identification (ID) and antimicrobial susceptibility
testing (AST) of the causative agent(s) of bloodstream
infections (BSI) are essential for the timely selection of
an appropriate antimicrobial therapy, which may result
in a better outcome for patients [1–4], and contribute to
contrast the emergence of antimicrobial resistance [5].
The current method requires that a positive blood cul-
ture (BC) is subcultured onto solid media before ID and
AST are performed by automated systems. To shorten
the turnaround time for diagnosis, several methods have
been proposed and evaluated, some of which with prom-
ising results [6–21].
In the present study, we aimed at establishing a method
able to provide rapid AST results, further referred to as
direct AST. To this aim, we used a CE approved system,
named Alfred 60AST (Alifax), initially conceived for urine
screening, and for AST of bacterial isolates from urine
[22]. In order to adapt the system to rapid AST from
positive blood cultures, two different protocols, proto-
col 1 (PR1) and protocol 2 (PR2), were evaluated, the
first using bacteria harvested from positive BC by
serum separator tubes, the second using a short-term
subculture of a positive BC in liquid medium. MALDI-
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TOF identification of bacteria contained in monomicro-
bial BC was performed by a recently described method,
further referred to as direct MALDI-TOF method [11].
The ID results obtained by the direct MALDI-TOF
method and the AST results obtained by PR1 and PR2
were compared with those by the method currently used
in our laboratory, further referred to as current method,
i.e. ID and AST on isolated colonies by MALDI-TOF and
Vitek 2 or Sensititre, respectively.
Methods
Blood samples
Blood specimens from patients admitted to the Pisa Uni-
versity Hospital (Italy) in the period July-December 2014
were inoculated into BC bottles [Plus Aerobic/F and
Plus Anaerobic/F, or Peds Plus F (Becton Dickinson &
Co, BD, Milan, Italy)], collected at the Unità Operativa
di Microbiologia, and transferred to the Bactec FX
instrument (Becton Dickinson, Franklin Lakes, NJ, USA)
for monitoring bacterial growth. From each patient, only
the first positive BC apparently monomicrobial at the
Gram staining was included in this study.
Identification and AST of bacteria by the current method
BC positive at the Bactec FX instrument were subjected
to Gram staining and subcultured onto appropriate solid
media. Isolated colonies were identified by MALDI-TOF
(Bruker Daltonics, Bremen, Germany) and AST was per-
formed by Vitek 2 (advanced Expert System software,
version R04.02C; bioMérieux, Marcy l’Étoile, France) or,
for Acinetobacter baumannii and Stenotrophomonas mal-
tophilia isolates, by the Sensititre Aris system (Trek Diag-
nostic Systems, Thermo Fisher Scientific, OH, USA). The
ID and AST results by the current method were used
as comparator for evaluation of results obtained by PR1
and PR2.
Identification and AST cards were tested periodically
for quality control assessment.
Identification of bacteria by the direct MALDI-TOF
method
Identification of bacteria by the direct MALDI-TOF
method was performed as previously described [11].
MALDI-TOF analysis was performed using a Microflex
LT system mass spectrometer following the manu-
facturer’s instructions. Captured spectra were analyzed
using a MALDI-TOF Biotyper automated control and
the Bruker Biotyper 3.1 software and library (4624 iso-
lates) (Bruker Daltonics). For each plate, the instrument
was calibrated to validate the run.
Identification results by the direct MALDI-TOF method
were compared with those by MALDI-TOF on isolated
colonies, as reference. Discrepancies in identification were
resolved by Vitek 2.
Direct AST of bacteria
Direct AST of bacteria was performed by Alfred 60AST
(Alifax SpA, Polverara, PD, Italy) and carried out using
two different protocols, PR1 and PR2. By PR1, bacteria
were recovered from positive BC by serum separator
tubes (BD) as previously described [11]. Briefly, an eight-
ml sample of a positive blood culture was transferred to
serum separator tubes. Next, bacteria were sedimented
on the surface of the silicon layer of the vacutainer tube
by centrifugation at 2,000 × g for 10 min, and suspended
at 0.9 McFarland in vials containing 2 ml HB&L broth
(Alifax). The bacterial suspension was transferred into
an AST-Empty vial and loaded in the refrigerated area
dedicated to external samples, called “External Samples
Zone” of the Alfred 60AST system. By PR2, 20 μl of
positive BC were inoculated into 2 ml HB&L broth and
loaded in the thermostat of the Alfred 60AST system for
monitoring the bacterial growth up to 0.5 McFarland.
Next, the instrument automatically transferred the sample
into an AST-Empty vial, placed in the refrigerated area
“Alfred Sample Zone”. The time needed to reach a bacter-
ial density corresponding to 0.5 McFarland was 1–4 h,
depending on the bacterial species (6 h for S. maltophilia).
Lyophilized antibiotics (Alifax) were dissolved in 2 ml
regenerating solution, and stored at 4 °C for up to 6 days
(3 days for meropenem). The regenerated antibiotics
were loaded into the “Alfred Antibiotic Zone”. The an-
tibiotics tested were: levofloxacin and gentamicin for all
Gram-negative bacteria; cefotaxime, ceftazidime and mer-
openem for Enterobacteriaceae, and amikacin and colistin
for nonfermenters; linezolid and teicoplanin for all Gram-
positive cocci; cefoxitin for staphylococci, and ampicillin
for streptococci.
For each strain a panel of antibiotics was established on
the basis of antibiotics available for this system at the time
we started this study, and on the basis of the time needed
to perform the test. We preferably selected antibiotics re-
quiring three hours incubation instead of five. Each anti-
biotic was CE approved. The vials, each containing 2 ml
HB&L broth, were put in the thermostat, and automatic-
ally loaded with the bacterial suspension (100 μl) and the
selected antibiotic (200 μl) for both PR1 and PR2. One vial
was loaded only with the bacterial suspension and used as
a positive control for bacterial growth.
Interpretation of AST results and data analyses
The antimicrobial activity of the tested antibiotics (by
PR1 and PR2) was calculated by the system as percent-
age of bacterial growth in comparison to the positive
control. The percentage of bacterial growth was auto-
matically translated into clinical categories: a growth
between 100 and 65 % was interpreted as resistant, be-
tween 65 and 50 % as intermediate, and < 50 % as sus-
ceptible (EUCAST-defined breakpoints [23]). The clinical
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categories obtained by the different methods were com-
pared with the results by the current method and
expressed as: agreement, very major errors (false sus-
ceptible), major errors (false resistant), and minor errors
(susceptible/resistant versus intermediate susceptibility).
Discrepancies between the results by direct AST (PR1 or
PR2) and the current method were resolved by Etest (AB
BioMerieux), which was performed according to the man-
ufacturer’s instructions.
The percentages of very major errors and major errors
were calculated according to the current ISO 20776–2
guideline. Major error rate was calculated based on the
number of susceptible strains tested as denominator;
very major error rate was calculated based on the num-
ber of resistant strains tested as denominator.
Statistical analysis was performed using the chi-square
test for independent pairs. The level of significance was
set at P < 0.05.
Results
Identification of bacteria from positive BC by direct
MALDI-TOF
A total of 194 positive BC were apparently monomicrobial
at the Gram staining, eleven (5.7 %) of which resulted to
be polymicrobial after subculture and were excluded from
this study. All monomicrobial BC contained either Gram-
negative bacilli or Gram-positive cocci. Eighty monomi-
crobial BC containing Gram-negative bacteria and 103
containing Gram-positive cocci were processed by the
direct MALDI-TOF method, with a mean identification
time of 25 min after BC positivity. In parallel, BC were
subcultured onto agar media for microbial identification
by the current method.
Identification of Gram-negative bacteria by the direct
MALDI-TOF method gave an interpretable result for 78
(97.5 %) of 80 BC (Table 1), 73 (91.3 %) of which with
scores > 2.0. The unidentified strains were correctly
identified by MALDI-TOF the day after on isolated
colonies. Duplicates were 100 % concordant and gave
similar scores. No strain was misidentified by the dir-
ect MALDI-TOF method. Identification of bacteria by
the direct and current methods by MALDI-TOF was
always concordant.
Identification of Gram-positive cocci by the direct and
current methods by MALDI-TOF gave concordant re-
sults for 99 (96.1 %) of the 103 BC, although only 45
(43.7 %) with scores ≥ 2.0 (Table 2). Duplicates were
100 % concordant and gave similar scores.
One Staphylococcus hominis was erroneously identified
by the direct method as Staphylococcus haemolyticus,
and one Streptococcus pneumoniae as Streptococcus
oralis group mitis. Furthermore, one S. hominis and one
Staphylococcus aureus strains were unidentified by the
direct method and correctly identified by MALDI-TOF
on isolated colonies.
Direct AST of Gram-negative bacilli
The AST results by PR1 and/or PR2 were available for all
the 80 Gram-negative isolates tested, 62 of which were
Enterobacteriaceae (Table 3) and 18 nonfermenters
(Table 4). The number of resistant, intermediate, and sen-
sitive strains for each antibiotic according to the current
method is reported as additional material in (Additional
file 1: Table S1). The AST by PR1 failed for 6 isolates
(1 Enterobacter cloacae, 2 P. aeruginosa, and 3 A.
baumannii), and by PR2 for other 6 (1K. pneumoniae, 1
Table 1 Gram-negative bacteria from monomicrobial blood cultures identified by the direct MALDI-TOF method
Species Correctly identified with score value of: Unidentified Total
3.000–2.300 2.299–2.000 1.999–1.700 <1.700
Escherichia coli 17 7 24
Klebsiella pneumoniae 12 11 1 1 25
Enterobacter aerogenes 1 1 2
Enterobacter cloacae 4 4
Morganella morganii 1 1 2
Serratia marcescens 1 1 2
Salmonella spp. 1 1
Proteus mirabilis 1 1
Raoultella ornithinolytica 1 1
Pseudomonas aeruginosa 5 3 2 1 1 12
Acinetobacter baumannii 3 3
Stenotrophomonas maltophilia 2 2
Acinetobacter ursingii 1 1
Total 38 35 4 1 2 80
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Serratia marcescens, 1 Acinetobacter ursingii, 1 P. aeru-
ginosa, and 2 S. maltophilia). Overall, the antimicrobial
susceptibility testing of Gram-negative bacilli (Tables 3
and 4) was assessed for a total of 353 (PR1) and 348
(PR2) isolate/antimicrobial agent combinations. Dis-
crepancies between the direct and current methods
were resolved by Etest, which revealed that AST was
correct by PR1 or PR2, but not by the current method,
for 15 (4.2) and 9 (2.6 %) isolate/antimicrobial agent
combinations, respectively, all of which, but one, regarding
Enterobacteriaceae. Complete AST agreement (i.e., AST
agreement for all tested antibiotics) was found for 35
(43.7) and 38 (47.5 %) out of the 80 isolates by PR1 and
PR2, respectively. The AST results of Gram-negative ba-
cilli and the total percent error as well as the percent error
for each antimicrobial agent are shown in Tables 3 and 4.
Together, concordant/correct AST for Gram-negative bac-
teria was found for 87.8 and 90.5 % of all isolate/antimicro-
bial combinations by PR1 and PR2, respectively. Notably,
AST agreement was higher than 90 % for cefotaxime,
Table 2 Gram-positive cocci from monomicrobial blood cultures identified by the direct MALDI-TOF method
Species Correctly identified with score value of: Unidentified Misidentified Total
3.000–2.300 2.299–2.000 1.999–1.700 <1.700
Staphylococcus epidermidis 8 21 13 42
Staphylococcus aureus 12 3 1 1 17
Staphylococcus hominis 5 4 2 1 1 13
Staphylococcus capitis 1 9 1 11
Staphylococcus haemolyticus 4 1 5
Staphylococcus warneri 1 1 2
Staphylococcus pettenkoferi 1 1
Staphylococcus sciuri 1 1
Staphylococcus lugdunensis 1 1
Enterococcus faecium 1 2 1 4
Enterococcus faecalis 1 1 1 3
Enterococcus casseliflavus 1 1
Streptococcus sanguinis 1 1
Streptococcus pneumoniae 1 1
Total 3 42 35 19 2 2 103
Table 3 Antimicrobial susceptibility testing of Enterobacteriaceae from positive blood cultures by PR1 (A)a and PR2 (B)a
Antimicrobial agent No. of very major errors No. of major errors No. of minor errors AST agreement Total
A
Cefotaxime (CTX) 0/40 1/19 (5.3 %) 2/59 (3.4 %) 56 (94.9 %) 59
Ceftazidime (CAZ) 0/32 10/25 (40 %) 4/60 (6.7 %) 46 (76.7 %) 60
Gentamicin (GM) 0/24 10/35 (28.6 %) 2/61 (3.3 %) 49 (80.3 %) 61
Levofloxacin (LEV) 0/34 0/26 (0 %) 0/60 60 (100 %) 60
Meropenem (MEM) 0/18 5/43 (11.6 %) 2/61 (3.3 %) 54 (88.5 %) 61
Total (%) 0/148 26/148 (17.6 %) 10/301 (3.3 %) 265 (88.1 %) 301
B
Cefotaxime (CTX) 6/39 (15.4 %) 0/19 0/58 52 (89.7 %) 58
Ceftazidime (CAZ) 0/31 1/24 (4.2 %) 3/58 (5.2 %) 54 (93.1 %) 58
Gentamicin (GM) 0/25 8/33 (24.2 %) 1/60 (1.7 %) 51 (85 %) 60
Levofloxacin (LEV) 0/34 0/24 0/58 58 (100 %) 58
Meropenem (MEM) 0/16 6/42 (14.3 %) 2/58 (3.5 %) 50 (86.2 %) 58
Total (%) 6/145 (4.1 %) 15/142 (10.6 %) 6/292 (2.1 %) 265 (90.7 %) 292
aUsing the results from the susceptibility testing of the bacteria by Vitek 2 as reference. In case of discrepancies between the two methods, the results for the
susceptibility testing were confirmed by E-test. Data are numbers (with percentages) of bacterial isolates for which the antimicrobial susceptibility testing was concord-
ant/correct or erroneous by PR1 (A) or PR2 (B)
Barnini et al. BMC Microbiology  (2016) 16:185 Page 4 of 8
levofloxacin, and amikacin by PR1, and for levofloxacin,
ceftazidime, amikacin, and colistin by PR2. In the overall,
no significant difference in accuracy was found between
PR1 and PR2 for Gram-negative bacteria (0.2 < P < 0.5).
For Enterobacteriaceae (Table 3), categorical AST
agreement was 88.1 by PR1, and 90.7 by PR2. By PR1,
there were 26/148 (17.6 %) major errors, and 10/301
(3.3 %) minor errors; by PR2, there were 6/145 (4.1 %)
very major errors, 15/142 (10.6 %) major errors, and 6/
292 (2.1 %) minor errors. All the very major errors were
observed for cefotaxime by PR2, whereas an AST agree-
ment of 94.9 % was observed by PR1 for this antibiotic.
On the contrary, ceftazidime reached significantly (p < 0.05)
higher AST agreement by PR2 (93.1 %) than by PR1
(76.7 %). Of interest, AST agreement for levofloxacin was
100 % by both PR1 and PR2. Comparable AST agreement,
below 90 %, was observed by PR1 and PR2 with gentamicin
and meropenem.
For nonfermenters (Table 4), categorical AST agreement
was 86.5 by PR1 and 89.3 by PR2. By PR1 there were 3/15
(20 %) very major errors, 2/37 (5.4 %) major errors, and 2/
52 (3.8 %) minor errors; by PR2 there were 1/16 (6.2 %)
very major errors, 2/40 (5 %) major errors, and 3/56
(5.3 %) minor errors. Of interest, AST agreement for ami-
kacin was 100 % by both PR1 and PR2. AST agreement
was 100 % also for colistin by PR2. AST agreement below
90 % was observed by PR1 and PR2 with gentamicin and
levofloxacin, and with colistin by PR1.
Direct AST of Gram-positive cocci
The AST results of 103 Gram-positive cocci were ana-
lysed, 76 (73.8 %) of which were coagulase-negative
staphylococci, 17 (16.5 %) S. aureus, 8 (7.8 %) Entero-
coccus spp., and 2 (1.9 %) streptococci; no profiles were
available for 1 S. epidermidis by PR1, and for 6 isolates (3
S. hominis, 1 S. aureus, 1 Enterococcus faecium, 1 S. pneu-
moniae) by PR2.
The antimicrobial susceptibility testing of Gram-
positive cocci (Tables 5 and 6) was performed for a total
of 305 and 290 isolate/antimicrobial agent combinations
by PR1 and PR2, respectively. Discrepancies in the AST
results between the direct and current methods were
resolved by Etest, which revealed that the AST was
correct by PR1 or PR2, but not by the current
method, for 13 (4.3) and 14 (4.8 %) isolate/antimicro-
bial agent combinations, respectively, all of which regard-
ing coagulase-negative staphylococci. The AST results by
PR1 and PR2 and the percent errors are shown in Tables 5
and 6. Complete AST agreement was found for 81
(78.6 %) isolates by PR1 and 79 (76.7 %) by PR2, and for
all S. aureus strains by PR1. Together, 93.1 and 93.8 % of
the isolate/antimicrobial agent combinations showed con-
cordant/correct AST results for Gram-positive cocci by
PR1 and PR2, respectively. Of note, AST agreement with
linezolid was 99 and 100 %, respectively, by PR1 and PR2.
No significant difference in accuracy was found between
PR1 and PR2 for Gram-positive cocci (0.5 < P < 0.9).
For staphylococci (Table 5), by PR1 there were 1/66
(1.5 %) very major errors, 12/210 (5.7 %) major er-
rors, and 5/276 (1.8 %) minor errors, and by PR2
there were 3/64 (4.7 %) very major errors, 11/203
(5.4 %) major errors, and 3/267 (1.1 %) minor errors.
All the very major errors were observed with cefoxi-
tin by both PR1 (one case) and PR2 (three cases).
AST agreement was higher than 90 % for all the anti-
biotics tested by PR1, and for all but cefoxitin by
PR2. Complete AST agreement was observed with li-
nezolid by PR2.
Table 4 Antimicrobial susceptibility testing of Gram-negative nonfermenters from positive blood cultures by PR1 (A)a or PR2 (B)a
Antimicrobial agent No. of very major errors No. of major errors No. of minor errors AST agreement Total
A
Amikacin (AMK) 0/3 0/10 0/13 13 (100 %) 13
Colistin (COL) 1/1 (100 %) 1/12 (8.3 %) 0/13 11 (84.6 %) 13
Gentamicin (GM) 1/2 (50 %) 1/11 (9.1 %) 0/13 11 (84.6 %) 13
Levofloxacin (LEV) 1/9 (11.1 %) 0/4 2/13 (15.4 %) 10 (76.9 %) 13
Total (%) 3/15 (20 %) 2/37 (5.4 %) 2/52 (3.8 %) 45 (86.5 %) 52
B
Amikacin (AMK) 0/4 0/10 0 14 (100 %) 14
Colistin (COL) 0/0 0/14 0 14 (100 %) 14
Gentamicin (GM) 1/3 (33.3 %) 2/11 (18.2 %) 1/14 (7.1 %) 10 (71.5 %) 14
Levofloxacin (LEV) 0/9 0/5 2/14 (14.3 %) 12 (85.7 %) 14
Total (%) 1/16 (6.2 %) 2/40 (5 %) 3/56 (5.3 %) 50 (89.3) 56
aUsing the results from the susceptibility testing of the bacteria by Vitek 2 as reference. In case of discrepancies, the results for the susceptibility testing were
confirmed by E-test. Data are numbers (with percentages) of bacterial isolates for which the antimicrobial susceptibility testing was concordant/correct or
erroneous by PR1 (A) or PR2 (B)
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For streptococci/enterococci (Table 6), representing
only 9.7 % of all the Gram-positive cocci tested, by PR1
there were 1/6 (16.7 %) very major errors, and 2/23
(8.7 %) major errors, and by PR2 there was 1/20 (5 %)
major error. Complete agreement for all isolates was ob-
served with linezolid by both PR1 and PR2, and with
ampicillin by PR2. AST agreement below 90 % was ob-
tained with teicoplanin by both PR1 and PR2, and with
ampicillin by PR1.
Discussion
In the last few years, the rapid development of MALDI-
TOF MS technology has allowed rapid bacterial species
identification directly from positive BC [10, 11, 24–30].
In the present study, direct MALDI-TOF analysis was
used for rapid identification of bacteria from monomi-
crobial BC, as previously described [11]. Concordant
identification of Gram-negative bacteria and Gram-
positive cocci by the direct MALDI-TOF method com-
pared to the current method was 97.5 % and 96.1 %,
respectively, supporting that direct MALDI-TOF can be
used efficiently for ID of bacteria in positive BC [11, 27,
29, 30]. However, it should be noted that only score
values ≥ 2.000 are considered as probable species iden-
tification. As we observed in a previous study, our data
strongly suggest that cut-off values could be lowered
down to 1.4 without compromising accuracy [11]. Similar
observations have been reported also by other authors
[28, 30, 31]. Therefore, the availability of rapid ID re-
sults by this method allowed proceeding with the selec-
tion of the proper antibiotic panel for direct AST on
the basis of those available for this new system. The
main finding from the present study is that the pro-
posed method for direct AST might be used to provide
clinicians with reliable AST results in a few hours. The
AST results of Gram-negative bacteria obtained by the
two different protocols, PR1 and PR2, were concord-
ant/correct with the results obtained by the current
method for 87.8 and 90.5 % of the isolate/antimicrobial
agent combinations, respectively. For Gram-negative
Table 6 Antimicrobial susceptibility testing of streptococci/enterococci from positive blood cultures by PR1 (A)a or PR2 (B)a
Antimicrobial agent No. of very major errors No. of major errors No. of minor errors AST Agreement Total
A
Ampicillin (AMP) 1/5 (20 %) 0/4 0/9 8 (88.9 %) 9
Linezolid (LZ) 0/0 0/10 0/10 10 (100 %) 10
Teicoplanin (TEI) 0/1 2/9 (22.2 %) 0/10 8 (80 %) 10
Total (%) 1/6 (16.7 %) 2/23 (8.7 %) 0/29 26 (89.7 %) 29
B
Ampicillin (AMP) 0/3 0/4 0/7 7 (100 %) 7
Linezolid (LZ) 0/0 0/8 0/8 8 (100 %) 8
Teicoplanin (TEI) 0/0 1/8 (12.5 %) 0/8 7 (87.5 %) 8
Total (%) 0/3 1/20 (5 %) 0/23 22 (95.7 %) 23
aUsing the results from the susceptibility testing of the bacteria by Vitek 2 as reference. In case of discrepancies, the results for the susceptibility testing were
confirmed by E-test. Data are numbers (with percentages) of bacterial isolates for which the antimicrobial susceptibility testing was concordant/correct or
erroneous by PR1 (A) or PR2 (B)
Table 5 Antimicrobial susceptibility testing of Staphylococcus species from positive blood cultures by PR1 (A)a or PR2 (B)a
Antimicrobial agent No. of very major errors No. of major errors No. of minor errors AST Agreement Total
A
Cefoxitin (CFX) 1/63 (1.6 %) 5/29 (17.2 %) 2/92 (2.2 %) 84 (91.3 %) 92
Linezolid (LZ) 0/3 1/89 (1.1 %) 0/92 91 (98.9 %) 92
Teicoplanin (TEI) 0/0 6/92 (6.5 %) 3/92 (3.3 %) 83 (90.2 %) 92
Total (%) 1/66 (1.5 %) 12/210 (5.7 %) 5/276 (1.8 %) 258 (93.5 %) 276
B
Cefoxitin (CFX) 3/61 (4.7 %) 4/28 (14.3 %) 3/89 (3.4 %) 79 (88.7 %) 89
Linezolid (LZ) 0/3 0/86 0/89 89 (100 %) 89
Teicoplanin (TEI) 0/0 7/89 (7.9 %) 0/89 82 (92.1 %) 89
Total (%) 3/64 (4.7 %) 11/203 (5.4 %) 3/267 (1.1 %) 250 (93.7 %) 267
aUsing the results from the susceptibility testing of the bacteria by Vitek 2 as reference. In case of discrepancies, the results for the susceptibility testing were
confirmed by E-test. Data are numbers (with percentages) of bacterial isolates for which the antimicrobial susceptibility testing was concordant/correct or
erroneous by PR1 (A) or PR2 (B)
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bacteria, levofloxacin showed an agreement in clinical
categories >90 % by both PR1 and PR2, with <3 % very
major errors and <7 % major and minor errors in combin-
ation, thus meeting the selection criteria for an antimicro-
bial susceptibility testing proposed by Jorgensen [32].
For Enterobacteriaceae, there was 100 % categorical
agreement for levofloxacin by both PR1 and PR2, 94.9 %
for cefotaxime by PR1 and 93.1 % for ceftazidime by
PR2. The lowest categorical agreement was found for
ceftazidime by PR1 (significantly lower than by PR2).
Unfortunately, meropenem and ceftazidime tests were
not available for nonfermenters. Although the number
of nonfermenters tested was low, 100 % categorical
agreement was observed with amikacin by PR1 and PR2,
and with colistin by PR2. Altogether, no significant dif-
ference in accuracy was found for Gram-negative bac-
teria between PR1 and PR2.
The AST results of Gram-positive cocci by PR1 and
PR2 were concordant/correct with the results obtained
by the current method for 93.1 and 93.8 % of the isolate/
antibiotic combinations, respectively. Cefoxitin (91.3 %)
and linezolid (99.0 %) by PR1, and linezolid (100 %) and
teicoplanin (91.8 %) by PR2 showed an agreement in
clinical categories >90 %, with linezolid meeting the selec-
tion criteria proposed by Jorgensen, both by PR1 and PR2.
With the only exception of cefoxitin (88.7 %) by PR2,
there was a categorical agreement >90 % for all the anti-
microbial agents tested on staphylococci by both PR1 and
PR2. Optimal results were obtained for S. aureus isolates
by PR1, with 17/17 isolates showing complete AST agree-
ment with the current method. Although the number of
streptococci/enterococci tested was low, 100 % categorical
agreement was observed with linezolid, by PR1 and PR2,
and ampicillin by PR2. In the overall, no significant differ-
ence in accuracy was found between PR1 and PR2 for
Gram-positive cocci. The time required by PR1 from
blood culture positivity to AST results is about 4 h, in-
cluding about 30 min to prepare the bacterial suspension
and obtaining ID results, and a three-hour incubation for
most of the tested antibiotics. For antibiotics requiring a
five-hour incubation, 6 h are needed to provide AST
results by PR1. The time required by PR2 from blood
culture positivity to AST results is more variable, de-
pending on the time required to reach the 0.5 McF
suspension (1–4 h) and the whole procedure may take
up to 9 h. On the bases of these observations, PR1 is to
be preferred to PR2.
Conclusions
The most relevant conclusion from the present study is
that the proposed method allows to yield rapid and re-
liable AST results, which often is of vital importance to
either confirm or streamline antibiotic therapy for patients
suffering from BSI. In addition, the earlier administration
of appropriate antimicrobial therapy will also reduce the
emergence of antimicrobial-resistant strains. The results
were particularly favorable for Gram-positive cocci, which
often yield less accurate results than Gram-negative bac-
teria when tested directly from positive BC. In particular,
100 % categorical agreement was found with levofloxacin
for Enterobacteriaceae by both PR1 and PR2, and 99.0 and
100 % categorical agreement was observed with linezolid
for Gram-positive cocci by PR1 and PR2, respectively. A
limitation of this study is that times to result were not
accurately measured. Further studies involving a higher
number of blood samples and antibiotics are needed to
fully evaluate the potential of this new method. Important
advancement in patient care in terms of clinical and finan-
cial benefits is to be expected by its implementation in
clinical microbiological laboratories.
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